Rapid Micro Biosystems, Inc. (RPID)
RPIDNASDAQ-CMBiotechnology: Laboratory Analytical Instruments
$0.7534
+0.0304 (+4.20%) today
At the close, Nov 10, 4:00 PM ET. After hours $0.7800 +3.53%
- Market cap
- $37.79m
- P/E
- –
- EPS, last 4 quarters
- $-1.12
- Dividend yield
- –
- Day range
- $0.7000 to $0.7600
- 52-week range
- $0.5801 to $4.94
- Average volume
- 245.4k
- Previous close
- $0.7230
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $3.00, +298.2% from here
Earnings
next estimate $-0.2000Next report Nov 13, 2026
Sep 2025
0.0%
Dec 2025
-21.7%
Mar 2026
-24.0%
Jun 2026
-3.9%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $7.84m | $11.28m | $8.00m | $8.05m |
| Gross profit | $696.0k | -$328.0k | $371.0k | $1.21m |
| Operating income | -$11.37m | -$12.21m | -$13.85m | -$12.32m |
| Net income | -$11.51m | -$12.50m | -$14.28m | -$12.92m |
Last four quarters: revenue $35.18m, margin -145.6%, free cash flow -$40.39m
News
8 latest- Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Misses Revenue EstimatesZacks · 5 days ago
- Tactile Systems Technology (TCMD) Q3 Earnings Surpass EstimatesZacks · Nov 2, 2026
- Rapid Micro Biosystems, Inc. (RPID) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks · Oct 30, 2026
- After Plunging 33.7% in 4 Weeks, Here's Why the Trend Might Reverse for Rapid Micro Biosystems (RPID)Zacks · Sep 4, 2026
- Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Rapid Micro Biosystems (RPID)Zacks · Aug 19, 2026
- Rapid Micro Biosystems (RPID) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 14, 2026
- Rapid Micro Biosystems (RPID) Upgraded to Buy: What Does It Mean for the Stock?Zacks · Aug 12, 2026
- Rapid Micro Biosystems Q2 Earnings Call HighlightsMarketBeat · Aug 7, 2026
The company
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control ('MQC') testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- rapidmicrobio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.